JP Morgan Maintains Overweight on Ascentage Pharma Group, Lowers Price Target to $33

JP Morgan analyst Brian Cheng has maintained an Overweight rating on Ascentage Pharma Group (NASDAQ: AAPG) but has lowered the price target from $46 to $33.